Celldex Therapeutics PT Raised to $34.00 (CLDX)
Investment analysts at Guggenheim lifted their price objective on shares of Celldex Therapeutics (NASDAQ:CLDX) from $26.00 to $34.00 in a note issued to investors on Tuesday, Analyst Ratings.Net reports. The firm currently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential downside of 0.79% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Cantor Fitzgerald raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) to $39.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Celldex Therapeutics (NASDAQ:CLDX) from $28.00 to $45.00 in a research note to investors on Monday. They now have an “outperform” rating on the stock. Finally, analysts at Wedbush reiterated a “buy” rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note to investors on Tuesday, September 17th. They now have a $35.00 price target on the stock.
One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Celldex Therapeutics currently has an average rating of “Buy” and an average price target of $32.50.
Shares of Celldex Therapeutics (NASDAQ:CLDX) traded up 4.87% on Tuesday, hitting $34.27. 4,784,835 shares of the company’s stock traded hands. Celldex Therapeutics has a 1-year low of $5.02 and a 1-year high of $34.28. The stock’s 50-day moving average is $23.29 and its 200-day moving average is $16.81. The company’s market cap is $2.775 billion.
Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.02. The company had revenue of $0.97 million for the quarter, compared to the consensus estimate of $1.57 million. During the same quarter in the previous year, the company posted ($0.23) earnings per share. The company’s revenue for the quarter was down 51.7% on a year-over-year basis. On average, analysts predict that Celldex Therapeutics will post $-0.97 earnings per share for the current fiscal year.
Celldex Therapeutics, Inc (NASDAQ:CLDX), is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.